Schizophrenia
|
0.380 |
Biomarker
|
disease |
BEFREE |
Meta-analysis established that the pooled prevalence of GAD65 autoantibodies was 5.8% (95% confidence interval [CI]: 2.0-15.6%; I<sup>2</sup> = 91%; nine studies) in psychotic disorders, with a prevalence of 4.6% (95%CI: 1.2-15.9%; nine studies; I<sup>2</sup> = 89%) and 6.2% (95%CI: 1.2-27.0%; two studies; I<sup>2</sup> = 69%) in schizophrenia and bipolar disorder, respectively.
|
28573688 |
2017 |
Schizophrenia
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Several of the genes in this network including epigenetic factors histone deacetylase 1 (HDAC1) and death-associated protein 6 (DAXX), the GABAergic enzyme GAD65 as well as the kainate receptor (KAR) subunits GluR6 and 7 show significant changes in expression in this area in SZ.
|
27733539 |
2017 |
Schizophrenia
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the patients with schizophrenia with completed suicide or positive nicotine exposure showed significantly higher expression of GAD2 full length transcript.
|
26848839 |
2016 |
Schizophrenia
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
In concert with previous studies, these findings suggest that schizoaffective disorder is associated with lower levels of both GAD65 and GAD67 mRNA and protein in the PFC, whereas subjects with schizophrenia have lower mean levels of only GAD67 mRNA and protein.
|
24993056 |
2015 |
Schizophrenia
|
0.380 |
Biomarker
|
disease |
BEFREE |
We used dual-label in situ hybridization to quantify GABA(A) α1 subunit mRNA expression in calcium/calmodulin-dependent kinase II α (CaMKIIα)-containing pyramidal cells and glutamic acid decarboxylase 65 kDa (GAD65)-containing interneurons in layer 3 of the PFC from matched schizophrenia and healthy comparison subjects.
|
21677653 |
2011 |
Schizophrenia
|
0.380 |
Biomarker
|
disease |
BEFREE |
These results suggest that GAD2 and GLUL do not play a major role in schizophrenia pathogenesis and there is no gene-gene interaction between the eight genes in the Japanese population.
|
19125103 |
2009 |
Schizophrenia
|
0.380 |
Biomarker
|
disease |
CTD_human |
Schizophrenia subjects showed significant decreases in mRNA levels of GAD(67), GAD(65), GAT-1, mGluR2, and neuronal nitric oxide synthase.
|
18923069 |
2008 |
Schizophrenia
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
Using the multifactor-dimensionality reduction method (MDR), we found that the interactions among the rs187269C/T polymorphism in the GABRB2 gene, the -243A/G polymorphism in the GAD2 gene and the 27379C/T and 661C/T polymorphisms in the GAD1 gene revealed a significant association with schizophrenia (P<0.001).
|
17412563 |
2007 |
Schizophrenia
|
0.380 |
GeneticVariation
|
disease |
LHGDN |
Using the multifactor-dimensionality reduction method (MDR), we found that the interactions among the rs187269C/T polymorphism in the GABRB2 gene, the -243A/G polymorphism in the GAD2 gene and the 27379C/T and 661C/T polymorphisms in the GAD1 gene revealed a significant association with schizophrenia (P<0.001).
|
17412563 |
2007 |
Schizophrenia
|
0.380 |
Biomarker
|
disease |
CTD_human |
This study demonstrates for the first time significant deficits in GABAergic markers Reelin and GAD 65 and 67 proteins in bipolar subjects and global deficits in the latter proteins in schizophrenia and mood disorders, accounting for the reported alterations in CSF/plasma levels of glutamate and GABA in these disorders.
|
15560956 |
2005 |
Schizophrenia
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Although the levels of GAD65 and GAD67 messages were increased in schizophrenia subjects, the proportion of the two GAD isoforms remained constant in controls and schizophrenics.
|
15114630 |
2004 |
Schizophrenia
|
0.380 |
AlteredExpression
|
disease |
LHGDN |
Although the levels of GAD65 and GAD67 messages were increased in schizophrenia subjects, the proportion of the two GAD isoforms remained constant in controls and schizophrenics.
|
15114630 |
2004 |
Seizures
|
0.340 |
Biomarker
|
phenotype |
BEFREE |
Enhanced susceptibility to stress and seizures in GAD65 deficient mice.
|
29377906 |
2018 |
Seizures
|
0.340 |
Biomarker
|
phenotype |
BEFREE |
Three of the seven patients with LE with different antibodies (NMDAR: n=1, Ma-2/Ta: n=1 and GAD65: n=1) achieved persistent seizure freedom along with no accelerated memory decline after surgery.
|
29253681 |
2018 |
Seizures
|
0.340 |
Biomarker
|
phenotype |
BEFREE |
In contrast patients with seizures related to GAD65-antibodies (an intracellular antigen) frequently develop epilepsy and have suboptimal response to treatment (including surgery).
|
28234800 |
2017 |
Seizures
|
0.340 |
GeneticVariation
|
phenotype |
BEFREE |
Using both a tagging and functional single nucleotide polymorphism (SNP) approach, we genotyped the GAD1 and GAD2 genes and linked them with PTS data, regarding time to first seizure, obtained for 257 adult subjects with severe TBI.
|
22840783 |
2013 |
Seizures
|
0.340 |
Biomarker
|
phenotype |
CTD_human |
Mice lacking the 65 kDa isoform of glutamic acid decarboxylase (GAD65) maintain normal levels of GAD67 and GABA in their brains but are susceptible to seizures.
|
8954991 |
1996 |
Seizures
|
0.340 |
Biomarker
|
phenotype |
CTD_human |
Labeling for GAD65 mRNA and associated protein is substantially increased in the remaining GABA neurons at 2-4 months after the initial seizure episode.
|
8985701 |
1996 |
Major Depressive Disorder
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
The best cut-off points to obtain high sensitivity values was 3, on both the PHQ-2 (major depressive disorder) and the GAD-2 (generalized anxiety disorder).
|
29549826 |
2018 |
Major Depressive Disorder
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
In addition, using quantitative RT-PCR, expression of GAD2 full length and truncated transcripts were measured in the DLPFC of patients with schizophrenia, bipolar disorder and major depression.
|
26848839 |
2016 |
Major Depressive Disorder
|
0.330 |
Biomarker
|
disease |
BEFREE |
We used real-time quantitative polymerase chain reaction (qPCR) to assess expression levels of two GABA synthesizing enzymes (glutamate decarboxylase; GAD65 and GAD67) and of three markers of GABA neuron subpopulations (PV, CR, SST) in the dorsolateral prefrontal cortex (DLPFC; Brodmann area 9) in triads (n=19) of control subjects and matched subjects with BPD or MDD.
|
21226980 |
2011 |
Alcoholic Intoxication, Chronic
|
0.330 |
Biomarker
|
disease |
BEFREE |
There are two isoforms of GAD, GAD1 and GAD2, which were reported to be associated with AD in males of Han Taiwanese (GAD1) and Russian (GAD2) ancestry.
|
19111404 |
2009 |
Alcoholic Intoxication, Chronic
|
0.330 |
Biomarker
|
disease |
BEFREE |
Analyses in these populations did not support a role for GAD2 in alcoholism.
|
17034009 |
2007 |
Alcoholic Intoxication, Chronic
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Three valid SNPs at the GAD2 gene demonstrated no associations with alcoholism.
|
17067345 |
2006 |
Major Depressive Disorder
|
0.330 |
Biomarker
|
disease |
CTD_human |
GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum.
|
15560956 |
2005 |